Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Sarah E. Hoffe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6232-8795; OpenAlex author ID A5024359439, A5035589941, A5122304652. Sources: ClinicalTrials.gov.

Their work

Papers
44 (first author 3, last author 7)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
145
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 2 papers · 2014: 2 papers · 2015: 7 papers · 2016: 3 papers · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers, 1 trial · 2022: 2 papers · 2023: 4 papers · 2024: 5 papers · 2025: 4 papers · 2026: 3 papers

Papers 44

  1. Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis. Co-author DOI 10.1093/jnci/djag235↗
  2. Implementing Timely Germline Genetic Testing for Patients With Pancreatic Cancer Using a Genetics Copilot for Point-of-Care Education and Health Assessment. Co-author DOI 10.1200/po-25-00807↗
  3. Dynamic tumor tracking for locally advanced pancreatic cancer: precision in motion. Co-author DOI 10.21037/tcr-2026-0588↗
  4. Early Supportive and Nutritional Care For Adults With Pancreatic Cancer: A Pilot Study. Co-author DOI 10.1016/j.jpainsymman.2025.07.032↗
  5. To irradiate or electroporate: how should we ablate pancreatic cancer? Last author DOI 10.21037/tgh-24-164↗
  6. Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy. Co-author DOI 10.3390/cancers17111797↗
  7. Personalizing Patient Education for Pancreatic Cancer Patients Receiving Multidisciplinary Care with Integration of Novel Digital Tools. Last author DOI 10.3390/healthcare13151929↗
  8. Support Through Remote Observation and Nutrition Guidance (STRONG), a digital health intervention to reduce malnutrition among pancreatic cancer patients: A st… Co-author DOI 10.1016/j.conctc.2024.101271↗
  9. SBRT for Pancreatic Cancer: A Radiosurgery Society Case-Based Practical Guidelines to Challenging Cases. Co-author DOI 10.1016/j.prro.2024.06.004↗
  10. Stereotactic body radiotherapy plus rucosopasem in locally advanced or borderline resectable pancreatic cancer: GRECO-2 phase II study design. Co-author DOI 10.2217/fon-2022-1219↗
  11. Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of t… Co-author DOI 10.3389/fonc.2024.1362244↗
  12. The Evolving Role of Neoadjuvant Radiation Therapy in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/jcm13226800↗
  13. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-control… Last author DOI 10.1016/s1470-2045(23)00478-3↗
  14. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic R… Co-author DOI 10.1177/10732748221150228↗
  15. Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1177/10732748231219069↗
  16. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  17. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection. Last author DOI 10.1007/s11605-021-05130-x↗
  18. Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation … Co-author DOI 10.1016/j.adro.2022.101045↗
  19. Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer. Co-author DOI 10.1186/s13014-021-01957-5↗
  20. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.21.01220↗
  21. Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic… Co-author DOI 10.1016/j.ijrobp.2020.09.022↗
  22. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unres… Co-author DOI 10.4103/eus.eus_44_19↗
  23. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Co-author DOI 10.1016/j.prro.2019.06.016↗
  24. Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival: A SEER Database Analysis. Co-author DOI 10.1097/coc.0000000000000261↗
  25. Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy. Last author DOI 10.21037/jgo.2017.09.13↗
  26. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy… Last author DOI 10.1080/0284186x.2016.1256497↗
  27. Outcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy. Co-author DOI 10.21037/jgo.2017.08.05↗
  28. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-015-5006-1↗
  29. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy co… Co-author DOI 10.21037/jgo.2016.03.15↗
  30. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. Co-author DOI 10.3978/j.issn.2078-6891.2015.075↗
  31. Comparative long-term outcomes of upfront resected pancreatic cancer after preoperative biliary drainage. Co-author DOI 10.1007/s00464-015-4075-3↗
  32. A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1007/s12029-015-9734-z↗
  33. Resected pancreatic cancer outcomes in the elderly. Co-author DOI 10.1016/j.jgo.2014.11.005↗
  34. Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. First author DOI 10.1016/j.radonc.2015.07.018↗
  35. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarc… First author DOI 10.3109/0284186x.2015.1004367↗
  36. Outcomes of resected pancreatic cancer in patients age ≥70. Co-author DOI 10.3978/j.issn.2078-6891.2015.038↗
  37. Management of borderline resectable pancreatic cancer. Co-author DOI 10.4251/wjgo.v7.i10.241↗
  38. Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. Co-author DOI 10.1002/cncr.28543↗
  39. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation. Co-author DOI 10.1016/j.semradonc.2013.11.002↗
  40. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Co-author DOI 10.1016/j.ijrobp.2013.02.022↗
  41. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. Co-author DOI 10.1200/jco.2012.44.7516↗
  42. Lessons learned from a complete remission of advanced metastatic pancreatic ductal adenocarcinoma. Co-author PMID 22706548↗
  43. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. First author DOI 10.1002/jso.21954↗
  44. Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer. Last author PMID 22368736↗

Trials 1

  1. Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer Principal investigator NCT03718650↗

Closest collaborators

The 25 strongest of 145 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jessica M. Frakes · 21 shared papers, 2015–2026 · strength 2.86
  2. Mokenge Peter Malafa · 24 shared papers, 2011–2026 · strength 2.43
  3. Pamela Joy Hodul · 22 shared papers, 2011–2026 · strength 2.19
  4. Russell F. Palm · 7 shared papers, 2021–2026 · strength 1.10
  5. Nicole Nardella · 5 shared papers, 2024–2026 · strength 0.96
  6. Joseph M. Herman · 8 shared papers, 2013–2025 · strength 0.91
  7. Gregory M. Springett · 17 shared papers, 2011–2018 · strength 0.87
  8. Jason W. Denbo · 5 shared papers, 2022–2025 · strength 0.85
  9. Jennifer B. Permuth · 3 shared papers, 2025–2026 · strength 0.83
  10. John Michael Bryant · 4 shared papers, 2022–2025 · strength 0.81
  11. Jason B. Fleming · 5 shared papers, 2021–2025 · strength 0.74
  12. Ravi Shridhar · 14 shared papers, 2011–2017 · strength 0.72
  13. Michael David Chuong · 8 shared papers, 2011–2024 · strength 0.72
  14. Dae Won Kim · 4 shared papers, 2023–2026 · strength 0.68
  15. Richard D. Kim · 4 shared papers, 2015–2026 · strength 0.57
  16. Dae Won Kim · 3 shared papers, 2023–2025 · strength 0.53
  17. Eric A. Mellon · 8 shared papers, 2013–2018 · strength 0.46
  18. Jason Gurewitz · 1 shared paper, 2026 · strength 0.43
  19. Todd Anthony Aguilera · 3 shared papers, 2020–2024 · strength 0.40
  20. Manisha Palta · 4 shared papers, 2019–2023 · strength 0.39
  21. Tobin Joel Crill Strom · 7 shared papers, 2015–2017 · strength 0.38
  22. William Adrian Hall · 3 shared papers, 2019–2024 · strength 0.37
  23. Karyn A. Goodman · 3 shared papers, 2019–2024 · strength 0.37
  24. Kea L. Turner · 2 shared papers, 2024–2025 · strength 0.35
  25. A. Alishani Tabriz · 2 shared papers, 2024–2025 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.